Methotrexate Injection Now Available for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Pediatric Rheumatology
Treatments Distinct for Black and White Children With Kawasaki Disease
Clinical outcomes of and treatment for Kawasaki disease were found to be distinct for Black and White children.
Cross-Cutting Disease Factors Predictive of Mental Health in Youth With Rheumatologic Disease
Study authors identified cross-cutting disease factors affecting the mental health of youth with rheumatologic disease.
Healthcare Providers Recognize Potential Benefits of Telemedicine in Pediatric Rheumatology During the COVID-19 Pandemic
During the COVID-19 pandemic, healthcare teams have realized the potential of telemedicine in pediatric rheumatology practices.
Early Initiation of Biologic Treatment Linked to Better Disease Outcomes in Juvenile Idiopathic Arthritis
Researchers analyzed the response to biologic treatment in juvenile idiopathic arthritis based on the timing of initiation of the treatment.
Imaging-Based Uveitis Surveillance Feasible for Patients With Juvenile Idiopathic Arthritis
Researchers investigated the feasibility, acceptability, and diagnostic performance of imaging-based surveillance for uveitis.
Elastography Ultrasound Feasible in Assessing Disease Activity in Pediatric-Onset Localized Scleroderma
Researchers determined the feasibility of elastography ultrasound in the assessment of pediatric-onset localized scleroderma.
Significant Temporal Association Between Arthritis and Uveitis Activity in Children With JIA-Associated Uveitis
Researchers determined the temporal association between arthritis and uveitis activity in children with juvenile idiopathic arthritis associated with uveitis.
Survey Reports Changes in Pediatric Rheumatology Practice During the COVID-19 Pandemic
A group of rheumatologists and researchers analyzed how the COVID-19 pandemic has affected pediatric rheumatology practice.
Golimumab Approved for Polyarticular JIA, Pediatric Psoriatic Arthritis
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.
-
Loading...
-
Loading...
Next post in Pediatric Rheumatology
